EcoR1 Capital, LLC bought AKTS

January 12, 2026 · Form 4 insider transaction

EcoR1 Capital, LLC bought 202,862 shares of Aktis Oncology, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.

Direction
Acquired (buy-side)
Shares
202,862
Price
N/A
Total value
N/A
Role
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateJanuary 12, 2026
Filing dateJanuary 12, 2026
Shares owned after202,862
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date.; These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.

View the original Form 4 on SEC EDGAR